Regeneus is a Sydney based regenerative medicine company. Founded in August 2007, Regeneus develops and commercialises proprietary cell-based technologies for the creation and manufacture of innovative cell treatments for humans and animals.
Regeneus' cell technologies enable the application of regenerative capacities of adipose derived cells (cells derived from fat) including mesenchymal stem cells (MSCs) for the treatment of musculoskeletal and other inflammatory conditions.
None of the content posted on this website should be considered financial advice. Click here for more information. Opinions expressed are those of the respective authors and do not represent the views of Aussie Stock Forums management. Digital Point modules: Sphinx-based search